Cleo Diagnostics Selects Bio-Techne's Platform as Immunoassay Instrument for Ovarian Cancer Blood Test; Shares Jump 3%

MT Newswires Live

02/18

Cleo Diagnostics (ASX:COV) selected Bio-Techne's Ella enzyme-linked immunosorbent assay platform as the immunoassay instrument for its ovarian cancer blood test, according to a Wednesday Australian bourse filing.

The companies are progressing discussions to enter into a binding agreement to start analytical validation of Cleo's test kits, the filing said. Cleo has been using the Ella platform in-house since September 2025 and confirmed the platform's capability to deliver its tests.

The finished kits will then be used test the around 500 blood samples collected as part of Cleo's pivotal clinical trial, per the filing.

Cleo Diagnostics' shares jumped nearly 3% in recent trading on Wednesday.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2612492145"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2612492145\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2612492145?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-18 10:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2612492145","market":"fut","top_or_hot":-1,"title":"Cleo Diagnostics Selects Bio-Techne's Platform as Immunoassay Instrument for Ovarian Cancer Blood Test; Shares Jump 3%","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/COV.AU\">Cleo Diagnostics</a> (ASX:COV) selected Bio-Techne's Ella enzyme-linked immunosorbent assay platform as the immunoassay instrument for its ovarian cancer blood test, according to a Wednesday Australian bourse filing.</p><p>The companies are progressing discussions to enter into a binding agreement to start analytical validation of Cleo's test kits, the filing said. Cleo has been using the Ella platform in-house since September 2025 and confirmed the platform's capability to deliver its tests.</p><p>The finished kits will then be used test the around 500 blood samples collected as part of Cleo's pivotal clinical trial, per the filing.</p><p>Cleo Diagnostics' shares jumped nearly 3% in recent trading on Wednesday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cleo Diagnostics Selects Bio-Techne's Platform as Immunoassay Instrument for Ovarian Cancer Blood Test; Shares Jump 3%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCleo Diagnostics Selects Bio-Techne's Platform as Immunoassay Instrument for Ovarian Cancer Blood Test; Shares Jump 3%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-02-18 10:12</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/COV.AU\">Cleo Diagnostics</a> (ASX:COV) selected Bio-Techne's Ella enzyme-linked immunosorbent assay platform as the immunoassay instrument for its ovarian cancer blood test, according to a Wednesday Australian bourse filing.</p><p>The companies are progressing discussions to enter into a binding agreement to start analytical validation of Cleo's test kits, the filing said. Cleo has been using the Ella platform in-house since September 2025 and confirmed the platform's capability to deliver its tests.</p><p>The finished kits will then be used test the around 500 blood samples collected as part of Cleo's pivotal clinical trial, per the filing.</p><p>Cleo Diagnostics' shares jumped nearly 3% in recent trading on Wednesday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TECH","symbol_name":"Techne Corporation","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2612492145","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2612492145","pubTimestamp":1771380745,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Cleo Diagnostics  selected Bio-Techne's Ella enzyme-linked immunosorbent assay platform as the immunoassay instrument for its ovarian cancer blood test, according to a Wednesday Australian bourse filing.The companies are progressing discussions to enter into a binding agreement to start analytical validation of Cleo's test kits, the filing said. Cleo has been using the Ella platform in-house since September 2025 and confirmed the platform's capability to deliver its tests.The finished kits will then be used test the around 500 blood samples collected as part of Cleo's pivotal clinical trial, per the filing.Cleo Diagnostics' shares jumped nearly 3% in recent trading on Wednesday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TECH":"Techne Corporation","BK7067":"生物科技","BK4121":"生命科学工具和服务","BK4585":"ETF&股票定投概念","IE00B19Z6F94.USD":"Legg Mason Royce - US Smaller Companies A Acc USD","IE00B64QTZ34.USD":"NEUBERGER BERMAN US SMALL CAP \"A\" (USD) ACC","BK4588":"碎股","COV.AU":"Cleo Diagnostics Ltd","IE0034390439.USD":"FTGF ROYCE US SMALLER COMPANIES \"A\" (USD) D"},"translate_title":"Cleo Diagnostics选择Bio-Techne的平台作为卵巢癌血液检测的免疫测定仪器；股价上涨3%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TECH":1.5,"COV.AU":1},"content_text":"Cleo Diagnostics (ASX:COV) selected Bio-Techne's Ella enzyme-linked immunosorbent assay platform as the immunoassay instrument for its ovarian cancer blood test, according to a Wednesday Australian bourse filing.The companies are progressing discussions to enter into a binding agreement to start analytical validation of Cleo's test kits, the filing said. Cleo has been using the Ella platform in-house since September 2025 and confirmed the platform's capability to deliver its tests.The finished kits will then be used test the around 500 blood samples collected as part of Cleo's pivotal clinical trial, per the filing.Cleo Diagnostics' shares jumped nearly 3% in recent trading on Wednesday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}